Abstract
Introduction Visceral adiposity is emerging as a key driver of cardio-metabolic risk factors and cardiovascular disease (CVD), but its relationship with cardiac structure and function is not well characterized across sexes. Using the Canadian Alliance for Healthy Heart and Minds (CAHHM), a large population-based cohort study, we sought to determine the association of visceral adipose tissue (VAT) on subclinical left ventricular (LV) remodeling in males and females.
Methods As part of the CAHHM study, 6522 participants free of clinical CVD (mean age: 57.4 [8.8 SD] years; 3,671 females, 56%) underwent magnetic resonance imaging (MRI) in which LV parameters and VAT volume were measured. Information about demographic factors, CV risk factors, and anthropometric measurements were obtained. Subclinical cardiac remodelling was defined as altered LV concentricity, represented by increased LV mass-to-volume ratio (LVMV).
Results Males had a higher VAT volume (80.8 mL; 95% CI: 74.6 t 86.9) compared to females (64.7 mL; 95% CI: 58.5 to 70.8), adjusted for age and height. Among both males and females, VAT was significantly associated with subclinical cardiac remodeling (increased LVMV), independent of other CV risk factors. In multiple regression models adjusted for cardiovascular risk factors, age, and height, every 1 sex-specific standard deviation increase in VAT corresponded to an increase of 0.037 g/mL in LVMV (95% CI: 0.032 to 0.041; p<0.001), which was consistent across both sexes. Notably, a 1 standard deviation increase in VAT is associated with a LVMV that is 20 times higher than what is observed with natural aging alone (0.0020 g/mL rise in LVMV (95% CI 0.0016 to 0.0025), and 1.5 times higher than the impact of an integrated measure of CV risk factors (0.024 g/mL; 95% CI: 0.020 to 0.028).
Conclusion VAT significantly influences subclinical cardiac remodeling in both males and females, independent of other cardiovascular risk factors and age. Further research to understand the pathways by which VAT contributes to accelerated cardiac aging is needed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
CAHHM was funded by the Canadian Partnership Against Cancer (CPAC), Heart and Stroke Foundation of Canada (HSF-Canada), and the Canadian Institutes of Health Research (CIHR). Financial contributions were also received from the Population Health Research Institute and CIHR Foundation Grant no. FDN-143255 to S.S.A.; FDN-143313 to J.V.T.; and FDN 154317 to E.E.S. In-kind contributions from A.R.M. and S.E.B. from Sunnybrook Hospital, Toronto for MRI reading costs, and Bayer AG for provision of IV contrast. The Canadian Partnership for Tomorrow Project is funded by the Canadian Partnership Against Cancer, BC Cancer Foundation, Genome Quebec, Ontario Institute for Cancer Research and Alberta Health and the Alberta Cancer Prevention Legacy Fund, Alberta Cancer Foundation. The PURE Study was funded by multiple sources. The Montreal Heart Institute Biobank is funded by Mr André Desmarais and Mrs France Chrétien-Desmarais and the Montreal Heart Institute Foundation. S.S.A. was supported by a Tier 1 Canada Research Chair in Ethnicity and Cardiovascular Disease (#CRC-2017-00024) and Heart and Stroke Foundation Chair in Population Health. P.A. was supported by a Ministry of Research and Innovation of Ontario Investigator Award. S.E.B. was supported by the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, and the Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto. E.L. was supported by the Laval University Chair of Research & Innovation in Cardiovascular Imaging and the Fonds de recherche du Québec-Santé. J.-C.T. holds the Tier 1 Canada Research Chair in translational and personalized medicine and the Université de Montréal Pfizer endowed research chair in atherosclerosis. Some of the data used in this research were made available by the Canadian Partnership for Tomorrow Project along with BC Generations Project, Alberta's tomorrow Project, Ontario Health Study, CARTaGENE, and the Atlantic PATH. Data were harmonized by Maelstrom and access policies and procedures were developed by the Centre of Genomics and Policy in collaboration with the Cohorts. Dr. Anand holds the Heart and Stroke Foundation Michael G DeGroote Chair in Population Health and a Canada Research Chair in Ethnic Diversity and Cardiovascular Disease. PURE-Mind Funding: The PURE study is an investigator-initiated study that was funded by the Population Health Research Institute, Hamilton Health Sciences Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, support from Canadian Institutes of Health Research's Strategy for Patient Oriented Research, through the Ontario SPOR Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies (with major contributions from AstraZeneca [Canada], Sanofi-Aventis [France and Canada], Boehringer Ingelheim [Germany and Canada], Servier, and GlaxoSmithKline) and additional contributions from Novartis and King Pharma and from various national or local organizations in participating countries. In Canada, there was additional support for the PURE study from an unrestricted grant from Dairy Farmers of Canada and the National Dairy Council (US), Public Health Agency of Canada, and Champlain Cardiovascular Disease Prevention Network. The PURE Poland substudy was partially funded by grant 290/W-PURE/2008/0 from the Polish Ministry of Science and Higher Education, and the MRI substudy was supported by grant NCN 2015/17/B/NZ7-02963 from the Polish National Science Centre. CG is supported by grants from the Swiss National Science Foundation (SNSF, # PP00P3_163892 and # PP00P3_190074), the Olga Mayenfisch Foundation, Switzerland, the OPO Foundation, Switzerland, the Novartis Foundation, Switzerland, the Swissheart Foundation, the Helmut Horten Foundation, Switzerland, the University Hospital Zurich (USZ) Foundation, the Iten-Kohaut Foundation, Switzerland, and the EMDO Foundation, Switzerland. Dr. Anand holds the Heart and Stroke Foundation Michael G DeGroote Chair in Population Health and a Canada Research Chair in Ethnic Diversity and Cardiovascular Disease. The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study complied with the Declaration of Helsinki, and each study site received institutional research ethics board approval for all procedures. All study participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Competing interests The University Hospital Zurich (CG) holds a research contract with GE Healthcare. Matthias G. Friedrich is board member, shareholder, and consultant of Circle Cardiovascular Imaging Inc.
Funding
CAHHM was funded by the Canadian Partnership Against Cancer (CPAC), Heart and Stroke Foundation of Canada (HSF-Canada), and the Canadian Institutes of Health Research (CIHR). Financial contributions were also received from the Population Health Research Institute and CIHR Foundation Grant no. FDN-143255 to S.S.A.; FDN-143313 to J.V.T.; and FDN 154317 to E.E.S. In-kind contributions from A.R.M. and S.E.B. from Sunnybrook Hospital, Toronto for MRI reading costs, and Bayer AG for provision of IV contrast. The Canadian Partnership for Tomorrow Project is funded by the Canadian Partnership Against Cancer, BC Cancer Foundation, Genome Quebec, Ontario Institute for Cancer Research and Alberta Health and the Alberta Cancer Prevention Legacy Fund, Alberta Cancer Foundation. The PURE Study was funded by multiple sources. The Montreal Heart Institute Biobank is funded by Mr André Desmarais and Mrs France Chrétien-Desmarais and the Montreal Heart Institute Foundation. S.S.A. was supported by a Tier 1 Canada Research Chair in Ethnicity and Cardiovascular Disease (#CRC-2017-00024) and Heart and Stroke Foundation Chair in Population Health. P.A. was supported by a Ministry of Research and Innovation of Ontario Investigator Award. S.E.B. was supported by the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, and the Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto. E.L. was supported by the Laval University Chair of Research & Innovation in Cardiovascular Imaging and the Fonds de recherche du Québec—Santé. J.-C.T. holds the Tier 1 Canada Research Chair in translational and personalized medicine and the Université de Montréal Pfizer endowed research chair in atherosclerosis. Some of the data used in this research were made available by the Canadian Partnership for Tomorrow Project along with BC Generations Project, Alberta’s tomorrow Project, Ontario Health Study, CARTaGENE, and the Atlantic PATH. Data were harmonized by Maelstrom and access policies and procedures were developed by the Centre of Genomics and Policy in collaboration with the Cohorts. Dr. Anand holds the Heart and Stroke Foundation Michael G DeGroote Chair in Population Health and a Canada Research Chair in Ethnic Diversity and Cardiovascular Disease. PURE-Mind Funding: The PURE study is an investigator-initiated study that was funded by the Population Health Research Institute, Hamilton Health Sciences Research Institute, the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario, support from Canadian Institutes of Health Research’s Strategy for Patient Oriented Research, through the Ontario SPOR Support Unit, as well as the Ontario Ministry of Health and Long-Term Care and through unrestricted grants from several pharmaceutical companies (with major contributions from AstraZeneca [Canada], Sanofi-Aventis [France and Canada], Boehringer Ingelheim [Germany and Canada], Servier, and GlaxoSmithKline) and additional contributions from Novartis and King Pharma and from various national or local organizations in participating countries. In Canada, there was additional support for the PURE study from an unrestricted grant from Dairy Farmers of Canada and the National Dairy Council (US), Public Health Agency of Canada, and Champlain Cardiovascular Disease Prevention Network. The PURE Poland substudy was partially funded by grant 290/W-PURE/2008/0 from the Polish Ministry of Science and Higher Education, and the MRI substudy was supported by grant NCN 2015/17/B/NZ7-02963 from the Polish National Science Centre.
CG is supported by grants from the Swiss National Science Foundation (SNSF, # PP00P3_163892 and # PP00P3_190074), the Olga Mayenfisch Foundation, Switzerland, the OPO Foundation, Switzerland, the Novartis Foundation, Switzerland, the Swissheart Foundation, the Helmut Horten Foundation, Switzerland, the University Hospital Zurich (USZ) Foundation, the Iten-Kohaut Foundation, Switzerland, and the EMDO Foundation, Switzerland. Dr. Anand holds the Heart and Stroke Foundation Michael G DeGroote Chair in Population Health and a Canada Research Chair in Ethnic Diversity and Cardiovascular Disease.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
